Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 791 across all filing types
Latest filing 2025-06-10 Declaration of Voting R…
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Voting Rights and Shares Capital of the Company
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "VOTING RIGHTS AND SHARES CAPITAL OF THE COMPANY" and explicitly references French Commercial Code articles related to the total number of voting rights and shares outstanding as of a specific date (May 31, 2025). It provides a table detailing the 'Number of Shares Outstanding' and 'Total number of voting rights' (theoretical and exercisable). This type of mandatory disclosure regarding the capital structure and voting power directly relates to the official count of shares and associated rights, which is often announced separately from major financial reports or general meeting results. While it touches upon voting rights, it is a periodic disclosure of the capital base, not the results of a vote (DVA) or a general meeting announcement (AGM-R). It is a specific regulatory disclosure concerning share capital structure. Given the options, this is best classified as a specific regulatory filing concerning share capital changes or status, which aligns most closely with Share Issue/Capital Change (SHA) or, if viewed as a general mandatory disclosure not fitting other specific categories, potentially Regulatory Filings (RNS). However, since it is a direct report on the total number of voting rights and shares, which is a fundamental component of capital structure reporting, SHA is the most appropriate fit among the specific codes, although it is not a transaction (POS) or a new issue announcement. Since it is a mandatory disclosure of the current share capital base, and not a transaction, the closest fit among the specific codes related to capital structure is SHA. If it were purely a notification of a threshold crossing by a third party, it would be MRQ. Since it is the company reporting its own total count, SHA is the best fit for capital structure reporting.
2025-06-10 English
NANOBIOTIX participera à la conférence investisseurs annuelle Jefferies Global Healthcare
Regulatory Filings Classification · 100% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces that NANOBIOTIX will participate in the JEFFERIES GLOBAL HEALTHCARE ANNUAL INVESTORS CONFERENCE, specifying the date, time, location, and participant (CFO). This is an announcement about an upcoming investor event, not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed presentation (IP). Since it is an announcement regarding an investor-facing event, it fits best under the general category of Investor Relations communication. Given the provided options, this type of forward-looking event announcement is often categorized as a general Regulatory Filing (RNS) if a more specific category like 'Investor Presentation' (IP) or 'Earnings Release' (ER) does not apply. However, since it is specifically about participation in an investor conference, it is a form of investor communication. It is not a proxy statement (PSI), dividend notice (DIV), or management discussion (MDA). It is closest to a general announcement about investor engagement. I will classify it as RNS as it is a general regulatory/corporate announcement that doesn't fit the highly specific financial report categories, although it is investor-focused.
2025-05-28 French
NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference
Regulatory Filings Classification · 100% confidence The document is explicitly titled "PRESS RELEASE" and announces the company's management participation in an upcoming external investor conference (Jefferies Global Healthcare Investor Conference). It provides details about the event (date, time, location, presenters) and includes a webcast link. This type of announcement, which informs investors about management's schedule for engaging with the market outside of standard regulatory filings or earnings calls, is best classified as a general Investor Presentation or announcement related to investor engagement. However, none of the specific codes perfectly match a 'Conference Participation Announcement'. Reviewing the definitions: - ER (Earnings Release): No financial results are presented. - IP (Investor Presentation): This is not a presentation document itself, but an announcement *about* participation. - RNS (Regulatory Filings): This is a broad fallback. Since the core purpose is to inform investors about management's schedule for external engagement, and it is a short press release format, it most closely aligns with general investor communication that doesn't fit the highly specific categories like ER, CT, or IP (which usually implies the presentation slides themselves). Given the options, this is a general corporate announcement. If a specific 'Conference Participation' code existed, it would be used. In its absence, and because it is a formal announcement intended for investors, it is often grouped with Investor Relations materials. However, the closest fit among the provided options for an announcement that is not a formal report or earnings release, but rather a scheduled event update, is often the general Regulatory Filings (RNS) or sometimes loosely associated with Investor Presentation (IP) if the context implies future presentation material. Since this is a press release announcing *participation* rather than the presentation itself, RNS is the most appropriate fallback for a non-standard, non-financial-result announcement. Revisiting the definitions, the document is a press release announcing participation in an investor conference. This is a common type of filing. It is not a DEF 14A, 10-K, ER, or CT. It is not a report itself (RPA rule does not apply as it's not announcing the publication of a report). It is an announcement of management activity. Given the options, and recognizing this is a standard corporate communication about investor engagement, RNS (Regulatory Filings / General Announcement) is the safest classification when a specific 'Conference Participation' code is missing.
2025-05-28 English
Nanobiotix Provides First Quarter 2025 Operational and Financial Update
Earnings Release Classification · 99% confidence The document is explicitly titled "*PRESS RELEASE*" and begins with "NANOBIOTIX PROVIDES FIRST QUARTER 2025 OPERATIONAL AND FINANCIAL UPDATE". It details operational milestones (dosing first patient, data presentations) and key financial figures (€39.8 million cash as of March 31, 2025) for the first quarter. This structure—a press release summarizing recent operational progress and key financial results for a specific interim period (Q1 2025)—is the defining characteristic of an Earnings Release (ER). It is not the comprehensive Annual Report (10-K) or the detailed Interim Report (IR), but rather the initial announcement of the period's results. Q1 2025
2025-05-21 English
Nanobiotix fait le point sur sa trésorerie et son activité opérationnelle du premier trimestre 2025
Earnings Release Classification · 98% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and provides an update on Nanobiotix's treasury position and operational activity for the First Quarter of 2025 ("PREMIER TRIMESTRE 2025"). It details key operational milestones (clinical trial progress, data presentations) and financial highlights (cash position, treasury runway extension due to an agreement amendment). This structure—a brief announcement summarizing recent performance, operational updates, and financial status for a specific reporting period (Q1 2025)—is characteristic of an Earnings Release (ER). It is not the full, comprehensive report (like a 10-K or IR), nor is it a transcript (CT) or a general regulatory filing (RNS). The document explicitly states the cash position as of March 31, 2025, which aligns with quarterly reporting cycles. Q1 2025
2025-05-21 French
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de commerce and Règlement Général de l'Autorité des Marchés Financiers - AMF) and provides a table detailing the total number of shares and voting rights as of a specific date (April 30, 2025). This type of mandatory periodic disclosure regarding the total share capital and voting rights structure is a specific regulatory filing in France, often related to major shareholding notifications or capital structure transparency. Among the provided codes, 'MRQ' (Major Shareholding Notification) is the closest fit as it deals with changes in share ownership levels, although this specific report is about the total capital base. However, given the content is a mandatory disclosure about the total number of shares and voting rights, it is a fundamental capital structure update. Since there isn't a specific code for 'Total Voting Rights Disclosure', and it is a mandatory regulatory announcement, it falls under the scope of capital structure changes or major shareholding transparency. 'MRQ' covers changes in significant share ownership thresholds, which is related to the underlying data provided. Alternatively, 'RNS' (Regulatory Filings) is a fallback. Given the precise nature of the data (total shares/votes), and its regulatory basis, it is most closely aligned with disclosures related to share capital structure changes, which often trigger MRQ filings if thresholds are crossed, or it is a standalone capital disclosure. Since the document explicitly details the total number of shares and voting rights, which is a key component of capital structure reporting, and it is a formal regulatory communication, I will classify it as a specific capital/share structure disclosure. 'SHA' is for new share issues/splits, which is not exactly this. 'MRQ' relates to changes in *significant* ownership. Since this is a mandatory monthly disclosure of the *total* capital base, and it is a formal regulatory communication, 'RNS' (Regulatory Filings) is the safest general classification for mandatory, non-standard reports, but 'MRQ' often encompasses these base capital disclosures when they are required periodically. Given the context of French regulation and the focus on the total number of shares/votes, this is a fundamental capital structure disclosure. I will select 'MRQ' as it relates to the transparency of share capital structure, which is often linked to major shareholding rules, or 'RNS' as a general regulatory filing. Given the specific nature of the data (total shares/votes), and the lack of a perfect fit, 'RNS' is the most appropriate fallback for a mandatory regulatory disclosure that doesn't fit the other specific categories like DIV, CAP, or SHA. However, if we interpret 'MRQ' broadly as any notification related to the structure of ownership/capital base, it fits better than the general fallback. Let's re-evaluate: This is a mandatory disclosure of the total share capital and voting rights, often required by AMF rules regardless of threshold crossing. This is a core capital structure transparency report. 'SHA' is for *issuance/change*. 'MRQ' is for *significant ownership change*. Since this is a monthly report on the *total* base, 'RNS' is the most accurate general regulatory filing code when a more specific one (like 10-K, ER, IR) is missing. I will use RNS as the general regulatory filing category for this specific French capital base disclosure.
2025-05-14 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.